Y Other financial liabilities (current) Z Other current liabilities (iv) Significant adjustments to consolidated statement of cash flows for the year ended 31 March 2013 (Presentation) Short-term finance lease liabilities and guaranty deposits  received included in “Other” as current liabilities under Japanese  GAAP have been included in “Other financial liabilities” (current)  under IFRS. (Presentation) Income tax payable included in “Other” as current liabilities  under Japanese GAAP has been presented separately as  “Income tax payable” under IFRS. Significant difference between the consolidated statements  of cash flows prepared and disclosed in accordance with  Japanese GAAP and those prepared and disclosed in  accordance with IFRS are as follows: The expenditures associated with research and develop- ment were classified as cash flows from operating activities  under Japanese GAAP because they were expensed as  incurred, while under IFRS, the capitalised research and devel- opment costs have been classified as cash flows from invest- ing activities. Liabilities arising from certain in-licensing agreements were  included in “Other” as current liabilities under Japanese GAAP.  However, they have been included in “Trade and other pay- ables” (current) under IFRS. Certain liabilities included in “Accrued expenses” separately  presented as current liabilities under Japanese GAAP have  been included in “Other current liabilities” under IFRS. (Recognition and measurement) Accrued paid absences of ¥4,841 million not recognised under  Japanese GAAP have been recognised and included in “Other  current liabilities” under IFRS. Astellas Pharma Inc.  _ Annual Report 2014 164